| Item type: | Article | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journal or Publication Title: | The Journal of antimicrobial chemotherapy | ||||||||||||||||||||||||||||||||||||
| Publisher: | OXFORD UNIV PRESS | ||||||||||||||||||||||||||||||||||||
| Place of Publication: | OXFORD | ||||||||||||||||||||||||||||||||||||
| Volume: | 66 | ||||||||||||||||||||||||||||||||||||
| Number of Issue or Book Chapter: | 10 | ||||||||||||||||||||||||||||||||||||
| Page Range: | pp. 2330-2335 | ||||||||||||||||||||||||||||||||||||
| Date: | 2011 | ||||||||||||||||||||||||||||||||||||
| Institutions: | Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Prof. Wiegrebe | ||||||||||||||||||||||||||||||||||||
| Identification Number: |
| ||||||||||||||||||||||||||||||||||||
| Classification: |
| ||||||||||||||||||||||||||||||||||||
| Keywords: | RESPIRATORY-TRACT INFECTIONS; ADULT PATIENTS; 400 MG; PENETRATION; CIPROFLOXACIN; DISPOSITION; fluoroquinolones; volume of distribution; size descriptor; HPLC | ||||||||||||||||||||||||||||||||||||
| Dewey Decimal Classification: | 600 Technology > 615 Pharmacy 600 Technology > 615 Pharmacy | ||||||||||||||||||||||||||||||||||||
| Status: | Published | ||||||||||||||||||||||||||||||||||||
| Refereed: | Yes, this version has been refereed | ||||||||||||||||||||||||||||||||||||
| Created at the University of Regensburg: | Partially | ||||||||||||||||||||||||||||||||||||
| Item ID: | 27986 |
Web of ScienceAbstract
Objectives: To assess the pharmacokinetics of moxifloxacin in morbidly obese patients. Methods: Twelve morbidly obese patients (2 male/10 female, age 25-61 years, weight 98-166 kg, body mass index 43.0-58.2 kg/m(2)) scheduled for gastric bypass surgery were treated with 400 mg of moxifloxacin orally once daily for 3 days and with 400 mg of moxifloxacin intravenously on day 4 (day of surgery). ...
Abstract
Objectives: To assess the pharmacokinetics of moxifloxacin in morbidly obese patients. Methods: Twelve morbidly obese patients (2 male/10 female, age 25-61 years, weight 98-166 kg, body mass index 43.0-58.2 kg/m(2)) scheduled for gastric bypass surgery were treated with 400 mg of moxifloxacin orally once daily for 3 days and with 400 mg of moxifloxacin intravenously on day 4 (day of surgery). Pharmacokinetic analysis was performed on day 1 and day 4. Specimens of small intestine, greater omentum and subcutaneous adipose tissue were collected intraoperatively 1.8-3.7 h after moxifloxacin infusion. Moxifloxacin concentrations were determined by HPLC. Results: The plasma pharmacokinetics (mean +/- SD) was comparable to historical data in normal-weight subjects. Oral bioavailability was 79.6% +/- 11.5%. After intravenous administration, plasma clearance was 9.6 +/- 2.0 L/h, volume of distribution was 165 +/- 30 L and area under the curve was 43.7 +/- 11.8 mg.h/L. Linear regression analysis showed the volume of distribution to be better correlated with ideal body weight, lean body weight, fat-free mass or height (R(2) = 0.60-0.67, P = 0.001-0.003) than with total body weight (R(2) = 0.46, P = 0.015). Whereas mean tissue concentrations in small intestine (6.99 +/- 2.34 mg/kg) were twice the concomitant plasma concentrations, the concentrations in greater omentum (0.801 +/- 0.168 mg/kg) or subcutaneous fat (0.638 +/- 0.180 mg/kg) were only one-quarter of those. Conclusions: The pharmacokinetics of moxifloxacin is not significantly affected by morbid obesity. No dose adjustment seems to be necessary in this particular population.
Metadata last modified: 29 Sep 2021 07:39
Altmetric